<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593332</url>
  </required_header>
  <id_info>
    <org_study_id>87549</org_study_id>
    <secondary_id>87549</secondary_id>
    <nct_id>NCT01593332</nct_id>
  </id_info>
  <brief_title>Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this project the investigators decide to evaluate the efficacy and safety of half dose
      mabthera (it means 500 mg infusion two weeks apart) in conventional drug resistant cases of
      rheumatoid arthritis. The investigators choose this drug because the use of anti-TNF drugs
      limited in the investigators refractory patients as the first line drugs because of its cost.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in 28-joint disease activity index( DAS28)</measure>
    <time_frame>Study duration was 6 months and the subjects were assessed for DAS 28 change at baseline, after 2 , 16 and 24 weeks.</time_frame>
    <description>disease activity score 28 formula which caculates based the number of tenderness and swelling of 28 joints and also ESR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in European league against rheumatism(EULAR) response criteria</measure>
    <time_frame>Change in EULAR 2,16,24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rituximab side effects</measure>
    <time_frame>0,2,16,24 weeks</time_frame>
    <description>side effects like infusion reaction , paresthesia, itching,hypertension or hypotension,headache and infection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>DMARD Resistant Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>two 500 mg rituximab infusions 2 weeks apart</description>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>500mg,two times with two weeks interval</description>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1987 ACR criteria for classification of RA

          -  Positive for rheumatoid factor(RF)

          -  Active RA despite therapy with conventional for at least 3 months as evidenced by DAS
             28 &gt; 3/2

          -  Patients with active, resistant RA who didn't receive anti TNF agents.

        Exclusion Criteria:

          -  Patient with hypogammaglobulinemia

          -  Patient with congestive heart failure (classIV)

          -  Active current bacterial,viral,fungal,myocardial or other infections

          -  Chronic hepatitis B or hepatitis C carriers

          -  History of severe allergic reaction to human,humanized or murine monoclonal antibodies

          -  History of malignancies

          -  Pregnant women or lactating mothers 8) Patients with Chronic renal failure and hepatic
             disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rheumatic Diseases Research Center, Mashhad University of Medical Sciences</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan Razavi</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>May 5, 2012</last_update_submitted>
  <last_update_submitted_qc>May 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Kamila Hashemzadeh</investigator_full_name>
    <investigator_title>assisstant professor</investigator_title>
  </responsible_party>
  <keyword>Rituximab</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Biologics</keyword>
  <keyword>Anti-tumour necrosis factor</keyword>
  <keyword>Disease-modifying anti-rheumatic drugs</keyword>
  <keyword>DAS28</keyword>
  <keyword>European League Against Rheumatism response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

